Two-Year Results for MC1273, a Phase 2 Evaluation of Aggressive Dose De- Escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma (OPSCC)Robert L. Foote, M.L. Hinni, Ashish V. Chintakuntlawar et al.|International Journal of Radiation Oncology*Biology*Physics|2017Cited by 16
Cost Savings of Aggressive Dose De-Escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma Versus Standard of Care; Cost Analysis of a Prospective Phase II StudyMark R. Waddle, Robert C. Miller, Jackson May et al.|International Journal of Radiation Oncology*Biology*Physics|2018Cited by 0